Shopping Cart 0
Cart Subtotal
USD 0

Inovio Pharmaceuticals Inc (INO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Inovio Pharmaceuticals Inc (Inovio) is a biotechnology company that focuses on developing a portfolio of DNA immunotherapies and vaccines for the treatment and prevention of various cancers and infectious diseases. The company develops products based on its core SynCon DNA plasmid technology and electroporation delivery technology. It is advancing a preclinical and clinical stage product pipeline to fight cancers of the cervix, prostate, breast, bladder, head and neck, lung, and pancreas; and to protect against and eliminate infectious diseases such as HIV, hepatitis, Ebola, Zika virus and Middle East respiratory syndrome (MERS). Inovio is headquartered in Plymouth Meeting, Pennsylvania, the US.

Inovio Pharmaceuticals Inc (INO)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Inovio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Inovio Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Inovio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Inovio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Inovio Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10

Inovio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Inovio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 13

Asset Purchase 13

Inovio Pharma Acquires DNA Therapies For Alzheimer's Disease And Multiple Sclerosis From Fudan University 13

Partnerships 14

Inovio Pharma Enters into Partnership with AIDS Malignancy Consortium 14

Inovio Pharma Enters into Partnership with Coalition for Epidemic Preparedness Innovations 15

Inovio Pharma and Parker Institute for Cancer Immunotherapy Enter into Agreement 16

Inovio Pharma Enters into Agreement with Genentech 17

Inovio Pharma and Regeneron Pharma Enter into Agreement 18

Inovio Pharma Partners with National Cancer Institute and Mayo Clinic 19

Inovio Pharma Enters into Research Agreement with Wistar Institute 20

GeneOne Life Science Enters into Research Agreement with Inovio Pharma 21

Inovio Pharma Enters into Co-Development Agreement with GeneOne Life Science 22

Inovio Pharma Amends Agreement with GeneOne 23

Path Malaria Vaccine Initiative And Inovio Pharma Partner To Accelerate Malaria Vaccine Development And Delivery Technologies 24

Licensing Agreements 25

MedImmune Enters into Licensing Agreement with Inovio Pharma 25

Equity Offering 26

Inovio Pharma Plans to Raise up to USD250 Million in Public Offering of Shares 26

Inovio Pharma Raises USD75 Million in Public Offering of Shares 27

Inovio Pharma to Raise up to USD35 Million in Private Placement of Shares 29

Inovio Pharma Raises USD6.3 Million in Public Offering of Shares 30

Inovio Pharma Raises USD87.4 Million Public Offering of Shares 31

Inovio Pharma Completes Public Offering Of Shares For USD 63.3 Million 33

Inovio Pharma Completes Public Offering Of Common Stock And Warrants For USD 15 Million 34

Inovio Pharmaceuticals Inc-Key Competitors 36

Inovio Pharmaceuticals Inc-Key Employees 37

Inovio Pharmaceuticals Inc-Locations And Subsidiaries 39

Head Office 39

Other Locations & Subsidiaries 39

Recent Developments 40

Financial Announcements 40

Aug 07, 2018: Inovio Pharmaceuticals reports 2018 second quarter financial results 40

May 09, 2018: Inovio Pharmaceuticals Reports 2018 First Quarter Financial Results 42

Mar 14, 2018: Inovio Pharmaceuticals Reports 2017 Fourth Quarter and Year End Financial Results 44

Nov 08, 2017: Inovio Pharmaceuticals Reports 2017 Third Quarter Financial Results 47

Aug 08, 2017: Inovio Pharmaceuticals Reports 2017 Second Quarter Financial Results 50

May 10, 2017: Inovio Pharmaceuticals Reports 2017 First Quarter Financial Results 53

Mar 15, 2017: Inovio Pharmaceuticals Reports 2016 Fourth Quarter and Year End Financial Results 55

Corporate Communications 58

May 24, 2018: Inovio Boosts Leadership Focused on Partnership and Grant Funding By Appointing Two New VPs for Business Development and R&D 58

Dec 11, 2017: Inovio Pharmaceuticals Promotes Dr. Laurent Humeau to Senior Vice President, Research & Development 59

Dec 06, 2017: Inovio Pharmaceuticals Appoints Wendy Yarno To its Board of Directors 60

Jun 28, 2017: Inovio Announces Leadership Appointments 61

Mar 21, 2017: George Bickerstaff Elected to Inovio's Board of Directors 62

Government and Public Interest 63

Feb 12, 2018: Inovio and The Wistar Institute Receive More Than USD 4.6 Million in R&D Funding to Advance Vaccines Against Tuberculosis & Malaria 63

Jan 18, 2018: The Wistar Institute Awarded More Than USD 1.4 Million to Create a Malaria Vaccine Through Synthetic DNA-Based Technology 64

Product News 65

Oct 08, 2018: Inovio Successfully Develops First DNA-Encoded Monoclonal Antibody (dMAb) Checkpoint Inhibitor and Demonstrates Tumor Shrinkage in Preclinical Studies 65

Sep 21, 2017: Inovio dMAb Constructs Shrink Prostate Tumors and Protect Against Lethal Antibiotic-Resistant Bacterial Infection In Preclinical Studies 67

09/18/2017: Inovio and Partners Initiate Phase 1/2a Clinical Trial To Further Advance Its Vaccine Against Deadly MERS Infection 69

Jul 06, 2017: Inovio's DNA-based Monoclonal Antibody Platform Achieves Further Proof-of-Principle Validation 70

Feb 27, 2017: Inovio's SynCon WT1 Cancer Antigen Breaks Tolerance, Highlights Potential for Universal Cancer Immunotherapy 72

Clinical Trials 74

May 21, 2018: Inovio Opens Phase 2 Trial for VGX-3100 in Third Indication To Treat HPV-The No. 1 Sexually Transmitted Disease 74

Nov 29, 2017: Inovio's Further Analysis of VGX-3100 Phase 2b Data Reveals Immune Correlates and Biomarker Signatures That Predicted Clinical Efficacy 75

Oct 24, 2017: Inovio and U.S. Army Co-developing Novel Vaccine That Completely Prevents Lethal Lassa Fever Infection in Pre-Clinical Study 77

Jun 08, 2017: Inovio Begins Phase 3 Clinical Trial of VGX-3100 for the Treatment of HPV-Related Cervical Pre-Cancer 78

Apr 24, 2017: Inovio Initiates Phase 2 Efficacy Trial with VGX-3100 For HPV-Related Vulvar Pre-Cancers 80

Feb 23, 2017: Inovio Reports New Positive Clinical Data on MERS Vaccine GLS-5300 81

Other Significant Developments 82

Jan 22, 2018: Inovio Pharmaceuticals' Published Universal Flu Vaccine Data Demonstrates Protective Responses Against All Major, Lethal H1N1 Influenza Viruses From the Last 100 Years in Animal Models 82

Appendix 83

Methodology 83

About GlobalData 83

Contact Us 83

Disclaimer 83


List Of Figure

List of Figures

Inovio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Inovio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Inovio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Inovio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Inovio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Inovio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Inovio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Inovio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Inovio Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Inovio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Inovio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Inovio Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Inovio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Inovio Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Inovio Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10

Inovio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Inovio Pharma Acquires DNA Therapies For Alzheimer's Disease And Multiple Sclerosis From Fudan University 13

Inovio Pharma Enters into Partnership with AIDS Malignancy Consortium 14

Inovio Pharma Enters into Partnership with Coalition for Epidemic Preparedness Innovations 15

Inovio Pharma and Parker Institute for Cancer Immunotherapy Enter into Agreement 16

Inovio Pharma Enters into Agreement with Genentech 17

Inovio Pharma and Regeneron Pharma Enter into Agreement 18

Inovio Pharma Partners with National Cancer Institute and Mayo Clinic 19

Inovio Pharma Enters into Research Agreement with Wistar Institute 20

GeneOne Life Science Enters into Research Agreement with Inovio Pharma 21

Inovio Pharma Enters into Co-Development Agreement with GeneOne Life Science 22

Inovio Pharma Amends Agreement with GeneOne 23

Path Malaria Vaccine Initiative And Inovio Pharma Partner To Accelerate Malaria Vaccine Development And Delivery Technologies 24

MedImmune Enters into Licensing Agreement with Inovio Pharma 25

Inovio Pharma Plans to Raise up to USD250 Million in Public Offering of Shares 26

Inovio Pharma Raises USD75 Million in Public Offering of Shares 27

Inovio Pharma to Raise up to USD35 Million in Private Placement of Shares 29

Inovio Pharma Raises USD6.3 Million in Public Offering of Shares 30

Inovio Pharma Raises USD87.4 Million Public Offering of Shares 31

Inovio Pharma Completes Public Offering Of Shares For USD 63.3 Million 33

Inovio Pharma Completes Public Offering Of Common Stock And Warrants For USD 15 Million 34

Inovio Pharmaceuticals Inc, Key Competitors 36

Inovio Pharmaceuticals Inc, Key Employees 37

Inovio Pharmaceuticals Inc, Subsidiaries 39

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Inovio Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Inovio Pharmaceuticals Inc (Inovio) is a biotechnology company that focuses on developing a portfolio of DNA immunotherapies and vaccines for the treatment and prevention of various cancers and infectious diseases. The company develops products based on its core SynCon DNA plasmid technology and electroporation delivery technology. It is advancing a preclinical and clinical stage product pipeline to fight cancers of the cervix, prostate, breast, bladder, head and neck, lung, and pancreas; and to protect against and eliminate infectious diseases such as HIV, hepatitis, Ebola, Zika virus and Middle East respiratory syndrome (MERS). Inovio is headquartered in Plymouth Meeting, Pennsylvania, the US.

Inovio Pharmaceuticals Inc (INO)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Inovio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Inovio Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Inovio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Inovio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Inovio Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10

Inovio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Inovio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 13

Asset Purchase 13

Inovio Pharma Acquires DNA Therapies For Alzheimer's Disease And Multiple Sclerosis From Fudan University 13

Partnerships 14

Inovio Pharma Enters into Partnership with AIDS Malignancy Consortium 14

Inovio Pharma Enters into Partnership with Coalition for Epidemic Preparedness Innovations 15

Inovio Pharma and Parker Institute for Cancer Immunotherapy Enter into Agreement 16

Inovio Pharma Enters into Agreement with Genentech 17

Inovio Pharma and Regeneron Pharma Enter into Agreement 18

Inovio Pharma Partners with National Cancer Institute and Mayo Clinic 19

Inovio Pharma Enters into Research Agreement with Wistar Institute 20

GeneOne Life Science Enters into Research Agreement with Inovio Pharma 21

Inovio Pharma Enters into Co-Development Agreement with GeneOne Life Science 22

Inovio Pharma Amends Agreement with GeneOne 23

Path Malaria Vaccine Initiative And Inovio Pharma Partner To Accelerate Malaria Vaccine Development And Delivery Technologies 24

Licensing Agreements 25

MedImmune Enters into Licensing Agreement with Inovio Pharma 25

Equity Offering 26

Inovio Pharma Plans to Raise up to USD250 Million in Public Offering of Shares 26

Inovio Pharma Raises USD75 Million in Public Offering of Shares 27

Inovio Pharma to Raise up to USD35 Million in Private Placement of Shares 29

Inovio Pharma Raises USD6.3 Million in Public Offering of Shares 30

Inovio Pharma Raises USD87.4 Million Public Offering of Shares 31

Inovio Pharma Completes Public Offering Of Shares For USD 63.3 Million 33

Inovio Pharma Completes Public Offering Of Common Stock And Warrants For USD 15 Million 34

Inovio Pharmaceuticals Inc-Key Competitors 36

Inovio Pharmaceuticals Inc-Key Employees 37

Inovio Pharmaceuticals Inc-Locations And Subsidiaries 39

Head Office 39

Other Locations & Subsidiaries 39

Recent Developments 40

Financial Announcements 40

Aug 07, 2018: Inovio Pharmaceuticals reports 2018 second quarter financial results 40

May 09, 2018: Inovio Pharmaceuticals Reports 2018 First Quarter Financial Results 42

Mar 14, 2018: Inovio Pharmaceuticals Reports 2017 Fourth Quarter and Year End Financial Results 44

Nov 08, 2017: Inovio Pharmaceuticals Reports 2017 Third Quarter Financial Results 47

Aug 08, 2017: Inovio Pharmaceuticals Reports 2017 Second Quarter Financial Results 50

May 10, 2017: Inovio Pharmaceuticals Reports 2017 First Quarter Financial Results 53

Mar 15, 2017: Inovio Pharmaceuticals Reports 2016 Fourth Quarter and Year End Financial Results 55

Corporate Communications 58

May 24, 2018: Inovio Boosts Leadership Focused on Partnership and Grant Funding By Appointing Two New VPs for Business Development and R&D 58

Dec 11, 2017: Inovio Pharmaceuticals Promotes Dr. Laurent Humeau to Senior Vice President, Research & Development 59

Dec 06, 2017: Inovio Pharmaceuticals Appoints Wendy Yarno To its Board of Directors 60

Jun 28, 2017: Inovio Announces Leadership Appointments 61

Mar 21, 2017: George Bickerstaff Elected to Inovio's Board of Directors 62

Government and Public Interest 63

Feb 12, 2018: Inovio and The Wistar Institute Receive More Than USD 4.6 Million in R&D Funding to Advance Vaccines Against Tuberculosis & Malaria 63

Jan 18, 2018: The Wistar Institute Awarded More Than USD 1.4 Million to Create a Malaria Vaccine Through Synthetic DNA-Based Technology 64

Product News 65

Oct 08, 2018: Inovio Successfully Develops First DNA-Encoded Monoclonal Antibody (dMAb) Checkpoint Inhibitor and Demonstrates Tumor Shrinkage in Preclinical Studies 65

Sep 21, 2017: Inovio dMAb Constructs Shrink Prostate Tumors and Protect Against Lethal Antibiotic-Resistant Bacterial Infection In Preclinical Studies 67

09/18/2017: Inovio and Partners Initiate Phase 1/2a Clinical Trial To Further Advance Its Vaccine Against Deadly MERS Infection 69

Jul 06, 2017: Inovio's DNA-based Monoclonal Antibody Platform Achieves Further Proof-of-Principle Validation 70

Feb 27, 2017: Inovio's SynCon WT1 Cancer Antigen Breaks Tolerance, Highlights Potential for Universal Cancer Immunotherapy 72

Clinical Trials 74

May 21, 2018: Inovio Opens Phase 2 Trial for VGX-3100 in Third Indication To Treat HPV-The No. 1 Sexually Transmitted Disease 74

Nov 29, 2017: Inovio's Further Analysis of VGX-3100 Phase 2b Data Reveals Immune Correlates and Biomarker Signatures That Predicted Clinical Efficacy 75

Oct 24, 2017: Inovio and U.S. Army Co-developing Novel Vaccine That Completely Prevents Lethal Lassa Fever Infection in Pre-Clinical Study 77

Jun 08, 2017: Inovio Begins Phase 3 Clinical Trial of VGX-3100 for the Treatment of HPV-Related Cervical Pre-Cancer 78

Apr 24, 2017: Inovio Initiates Phase 2 Efficacy Trial with VGX-3100 For HPV-Related Vulvar Pre-Cancers 80

Feb 23, 2017: Inovio Reports New Positive Clinical Data on MERS Vaccine GLS-5300 81

Other Significant Developments 82

Jan 22, 2018: Inovio Pharmaceuticals' Published Universal Flu Vaccine Data Demonstrates Protective Responses Against All Major, Lethal H1N1 Influenza Viruses From the Last 100 Years in Animal Models 82

Appendix 83

Methodology 83

About GlobalData 83

Contact Us 83

Disclaimer 83


List Of Figure

List of Figures

Inovio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Inovio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Inovio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Inovio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Inovio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Inovio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Inovio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Inovio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Inovio Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Inovio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Inovio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Inovio Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Inovio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Inovio Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Inovio Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10

Inovio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Inovio Pharma Acquires DNA Therapies For Alzheimer's Disease And Multiple Sclerosis From Fudan University 13

Inovio Pharma Enters into Partnership with AIDS Malignancy Consortium 14

Inovio Pharma Enters into Partnership with Coalition for Epidemic Preparedness Innovations 15

Inovio Pharma and Parker Institute for Cancer Immunotherapy Enter into Agreement 16

Inovio Pharma Enters into Agreement with Genentech 17

Inovio Pharma and Regeneron Pharma Enter into Agreement 18

Inovio Pharma Partners with National Cancer Institute and Mayo Clinic 19

Inovio Pharma Enters into Research Agreement with Wistar Institute 20

GeneOne Life Science Enters into Research Agreement with Inovio Pharma 21

Inovio Pharma Enters into Co-Development Agreement with GeneOne Life Science 22

Inovio Pharma Amends Agreement with GeneOne 23

Path Malaria Vaccine Initiative And Inovio Pharma Partner To Accelerate Malaria Vaccine Development And Delivery Technologies 24

MedImmune Enters into Licensing Agreement with Inovio Pharma 25

Inovio Pharma Plans to Raise up to USD250 Million in Public Offering of Shares 26

Inovio Pharma Raises USD75 Million in Public Offering of Shares 27

Inovio Pharma to Raise up to USD35 Million in Private Placement of Shares 29

Inovio Pharma Raises USD6.3 Million in Public Offering of Shares 30

Inovio Pharma Raises USD87.4 Million Public Offering of Shares 31

Inovio Pharma Completes Public Offering Of Shares For USD 63.3 Million 33

Inovio Pharma Completes Public Offering Of Common Stock And Warrants For USD 15 Million 34

Inovio Pharmaceuticals Inc, Key Competitors 36

Inovio Pharmaceuticals Inc, Key Employees 37

Inovio Pharmaceuticals Inc, Subsidiaries 39

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Inovio Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.